Natera (NASDAQ:NTRA) Receives Outperform Rating from Wolfe Research

Natera (NASDAQ:NTRA)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wolfe Research in a research note issued on Tuesday,Benzinga reports. They currently have a $260.00 target price on the medical research company’s stock. Wolfe Research’s price objective points to a potential upside of 18.82% from the stock’s current price.

Several other research firms have also weighed in on NTRA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. Wells Fargo & Company upped their price objective on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Piper Sandler reiterated an “overweight” rating and issued a $249.00 price objective on shares of Natera in a research note on Tuesday, May 12th. William Blair initiated coverage on Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. upped their price objective on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $256.81.

Natera Trading Down 2.0%

NTRA stock opened at $218.81 on Tuesday. Natera has a 1-year low of $131.81 and a 1-year high of $256.36. The firm has a market cap of $31.34 billion, a P/E ratio of -134.24 and a beta of 1.56. The business’s 50 day moving average is $202.69 and its 200-day moving average is $215.84.

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 1,688 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $204.10, for a total transaction of $344,520.80. Following the transaction, the insider owned 187,511 shares of the company’s stock, valued at approximately $38,270,995.10. This represents a 0.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 3,070 shares of the company’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $193.74, for a total value of $594,781.80. Following the transaction, the chief financial officer directly owned 58,291 shares in the company, valued at approximately $11,293,298.34. This represents a 5.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 34,406 shares of company stock worth $6,984,955 in the last quarter. 5.05% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NTRA. Integrated Wealth Concepts LLC lifted its holdings in Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after buying an additional 96 shares in the last quarter. NewEdge Advisors LLC lifted its stake in shares of Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after purchasing an additional 1,847 shares during the period. Focus Partners Wealth lifted its stake in shares of Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of Natera in the 2nd quarter valued at $298,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Natera in the 2nd quarter valued at $558,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.